{"groups":[{"description":"Patients receive oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Treatment (Kinase Inhibitor Therapy)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"All 13 participants were analyzed.","recruitmentDetails":"Thirteen participants were accrued from September 2007 to December 2008."}